An update on the impact of pre-transplant transfusions and allosensitization on time to renal transplant and on allograft survival

BMC Nephrology

Jeffrey Petersen⁴  Matthew Gitlin⁴  Mayank Bhanderi¹  Douglas J Norman⁵  Jonathan S Bromberg²  Juan C Scornik³ 

[1] HERON Health, Chandigarh, India;School of Medicine, University of Maryland, Baltimore, MD, USA;Department of Pathology, College of Medicine, University of Florida, Gainesville, FL, USA;Amgen Inc, Thousand Oaks, CA, USA;Oregon Health & Science University, Portland, OR, USA

关键词: Graft survival;    Renal transplant;    Allosensitization;    Transfusion;   

Others  :  1082822
DOI  :  10.1186/1471-2369-14-217

 received in 2013-08-01, accepted in 2013-10-01,  发布年份 2013

【 摘 要 】

Background

Blood transfusions have the potential to improve graft survival, induce sensitization, and transmit infections. Current clinical practice is to minimize transfusions in renal transplantation candidates, but it is unclear if the evidence continues to support pre-transplant transfusion avoidance. Changes in the Medicare prospective payment system may increase transfusion rates. Thus there is a need to re-evaluate the literature to improve the management options for renal transplant candidates.

Methods

A review applying a systematic approach and conducted using MEDLINE^®, Embase^®, and the Cochrane Library for English-language publications (timeframe: 01/1984–03/2011) captured 180 studies and data from publically available registries and assessed the impact of transfusions on allosensitization and graft survival, and the impact of allosensitization on graft survival and wait time.

Results

Blood transfusions continued to be a major cause of allosensitization, with allosensitization associated with increased rejection and graft loss, and longer wait times to transplantation. Although older studies showed a beneficial effect of transfusion on graft survival, this benefit has largely disappeared in the post-cyclosporine era due to improved graft outcomes with current practice. Recent data suggested that it may be the donor-specific antibody component of allosensitization that carried the risk to graft outcomes.

Conclusions

Results of this review indicated that avoiding transfusions whenever possible is a sound management option that could prevent detrimental effects in patients awaiting kidney transplantation.

【 授权许可】

   
2013 Scornik et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

【 参考文献 】

• [1]Pfaff WW, Howard RJ, Scornik JC, Day C, Renderer J, Scott J, Fennel RS, Peterson JC, Salomon DR, Patton PR: Incidental and purposeful random donor blood transfusion. Sensitization and transplantation. Transplantation 1989, 47(1):130-133.
• [2]Sautner T, Gnant M, Banhegyi C, Wamser P, Gotzinger P, Steininger R, Muhlbacher F: Risk factors for development of panel reactive antibodies and their impact on kidney transplantation outcome. Transpl Int 1992, 5(SUPPL. 1):S116-S120.
• [3]Macdougall IC: Novel erythropoiesis-stimulating agents: a new era in anemia management. Clin J Am Soc Nephrol 2008, 3(1):200-207.
• [4]Centers for Medicare & Medicaid Services: End-Stage Renal Disease Prospective Payment System. Regulation Number 1418-F. Available at http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/ESRDpayment/End-Stage-Renal-Disease-ESRD-Payment-Regulations-and-Notices.html webcite
• [5]Centers for Medicare & Medicaid Services: Final CY 2013 End-Stage Renal Disease Prospective Payment System. Regulation Number 1352-F. Available at http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/ESRDpayment/End-Stage-Renal-Disease-ESRD-Payment-Regulations-and-Notices.html webcite
• [6]USRDS: US Renal Data System, USRDS 2012 Annual data report: atlas of chronic kidney disease and end-stage renal disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; Available at http://www.usrds.org/atlas12.aspx webcite. Access date: April 2013
• [7]Chen W, Lee S, Colby J, Kluger J, Ashaye A, Tongbram V, Baker E, Mather J, Coleman CI, White CM: The impact of pre-transplant red blood cell transfusions in renal allograft rejection. Rockville, MD, USA: Agency for Healthcare Research and Quality. Technology Assessment Report; Project ID RENT0610; 2012. Available from: http://www.cms.gov/medicare-coverage-database/details/technology-assessments-details.aspx?TAId=78 webcite
• [8]The impact of pre-transplant red blood cell transfusions in renal allograft rejection. Available at http://www.cms.gov/determinationprocess/downloads/id78TA.pdf webcite. Access date: Feb 2012
• [9]Cyclosporine. Available at http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails webcite. Access date: Feb 2012
• [10]Downs SH, Black N: The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health 1998, 52(6):377-384.
• [11]Kennelly J: Methodological approach to assessing the evidence. In Reducing racial/ethnic disparities in reproductive and perinatal outcomes: the evidence from population-based interventions. Edited by Handler A, Kennelly J, Peacock N. New York, NY: Springer; 2011:7-19.
• [12]Cinti P, Pretagostini R, Arpino A, Tamburro ML, Mengasini S, Lattanzi R, De Simone P, Berloco P, Molajoni ER: Evaluation of pretransplant immunologic status in kidney-transplant recipients by panel reactive antibody and soluble CD30 determinations. Transplantation 2005, 79(5):599-601.
• [13]Cinti P, Pretagostini R, Lai Q, Tamburro ML, Rossi M, Poli L, Berloco P: Alloantibodies and outcomes of deceased donor kidney allografts. Hum Immunol 2009, 70(8):651-654.
• [14]Domingues EM, Matuck T, Graciano ML, Souza E, Rioja S, Falci MC, Monteiro De Carvalho DB, Porto LC: Panel reactive HLA antibodies, soluble CD30 levels, and acute rejection six months following renal transplant. Clin Transplant 2010, 24(6):821-829.
• [15]Ishida H, Tanabe K, Furusawa M, Ishizuka T, Hayashi T, Tokumoto T, Miyamoto N, Shirakawa H, Shimimura H, Shimizu T, et al.: Evaluation of flow cytometric panel reactive antibody in renal transplant recipients - examination of 238 cases of renal transplantation. Transpl Int 2005, 18(2):163-168.
• [16]Kimball PM, Baker MA, Wagner MB, King A: Surveillance of alloantibodies after transplantation identifies the risk of chronic rejection. Kidney Int 2011, 79(10):1131-1137.
• [17]Direskeneli H, Ozgun S, Ozener C, Lawrence R, Erman M, Sarsmaz N, Akoglu E: Anti-lymphocyte, anti-monocyte, and anti-endothelial cell antibodies in chronic haemodialysis patients. Nephrol Dial Transplant 1992, 7(5):422-426.
• [18]Hahn AB, Kasten-Jolly JC, Constantino DM, Graffunder E, Conti DJ: Promoter-region alleles of the TNF-(alpha) and IL-10 genes have no effect on pretransplant alloantibody production. Transplantation 2001, 72(4):739-742.
• [19]Koyle MA, Rajfer J, Mickey MR, Glassock RJ, Ward HJ: The current role of pre-transplant blood transfusions and tissue typing in cadaveric renal transplantation. J Urol 1987, 138(5):1141-1143.
• [20]Lietz K, Lao M, Paczek L, Gorski A, Gaciong Z: The impact of pretransplant erythropoietin therapy on late outcomes of renal transplantation. Ann Transplant 2003, 8(2):17-24.
• [21]Zou Y, Stastny P, Susal C, Dohler B, Opelz G: Antibodies against MICA antigens and kidney-transplant rejection. N Engl J Med 2007, 357(13):1293-1300.
• [22]Chequer Bou-Habib J, Krams S, Colombe BW, Lou C, Bubar O, Amend WJC, Salvatierra O Jr, Garovoy MR: Flow cytometric crossmatching and long-term kidney allograft survical in donor-specific transfusion patients. Transplantation 1991, 51(2):543-545.
• [23]Lim EC, Terasaki PI: High survival rate of kidney transplants in IgA nephropathy patients. Clin Transplant 1992, 6(2):100-105.
• [24]Soosay A, O’Neill D, Counihan A, Hickey D, Keogan M: Causes of sensitisation in patients awaiting renal transplantation in Ireland. Ir Med J 2003, 96(4):109-112.
• [25]Vanrenterghem Y, Waer M, Roels L, Coosemans W, Christaens MR, Opelz G: A prospective, randomized trial of pretransplant blood transfusions in cadaver kidney transplant candidates. Leuven Collaborative Group for Transplantation. Transpl Int 1994, 7(SUPPL.1):S243-S246.
• [26]Vathsala A, Chan SH, Wee C, Lim CH: Immunology of renal transplantation in Singapore. Ann Acad Med Singapore 1988, 17(2):218-225.
• [27]USRDS: US Renal Data System, USRDS 2010 Annual data report: atlas of chronic kidney disease and end-stage renal disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; Available at http://www.usrds.org/atlas10.aspx webcite. Access date: Jan 2012
• [28]Cicciarelli J, Terasaki PI, Mickey MR: The effect of zero HLA class I and II mismatching in cyclosporine-treated kidney transplant patients. Transplantation 1987, 43(5):636-640.
• [29]Iwaki Y, Cecka JM, Terasaki PI: The transfusion effect in cadaver kidney transplants - yes or no. Transplantation 1990, 49(1):56-59.
• [30]Opelz G, Vanrenterghem Y, Kirste G, Gray DWR, Horsburgh T, Lachance JG, Largiader F, Lange H, Vujaklija-Stipanovic K, varez-Grande J, et al.: Prospective evaluation of pretransplant blood transfusions in cadaver kidney recipients. Transplantation 1997, 63(7):964-967.
• [31]Takiff H, Cook DJ, Himaya NS, Mickey MR, Terasaki PI: Dominant effect of histocompatibility on ten-year kidney transplant survival. Transplantation 1988, 45(2):410-415.
• [32]Eigidi M, Scott DH, Corry RJ: The effect of transfusions on renal allograft survival in the cyclosporine era: a single center report. Clin Transplant 1993, 7(3):240-244.
• [33]Melzer JS, Husing RM, Feduska NJ: The beneficial effect of pretreatment blood transfusions in cyclosporine-treated cadaver renal allograft recipients. Transplantation 1987, 43(1):61-64.
• [34]Sanfilippo F, Thacker L, Vaughn WK: Living-donor renal transplantation in SEOPF. The impact of histocompatibility, transfusions, and cyclosporine on outcome. Transplantation 1990, 49(1):25-29.
• [35]Benfield MR, McDonald R, Sullivan EK, Stablein DM, Tejani A: The 1997 annual renal transplantation in children report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Pediatr Transplant 1999, 3(2):152-167.
• [36]Hiesse C, Busson M, Buisson C, Farahmand H, Bierling P, Benbunan M, Bedrossian J, Aubert P, Glotz D, Loirat C, et al.: Multicenter trial of one HLA-DR-matched or mismatched blood transfusion prior to cadaveric renal transplantation. Kidney Int 2001, 60(1):341-349.
• [37]Kerman RH, Kimball PM, Van Buren CT, Lewis RM, Kahan BD: Possible contribution of pretransplant immune responder status to renal allograft survival differences of black versus white recipients. Transplantation 1991, 51(2):338-342.
• [38]Poli F, Mascaretti L, Pappalettera M, Scalamonga M, Bernardi L, Sirchia G: HLA-DRB1 compatibility in cadaver kidney transplantation: correlation with graft survival and function. Transpl Int 1995, 8(2):91-95.
• [39]Hanish SI, Samaniego M, Mezrich JD, Foley DP, Leverson GE, Lorentzen DF, Sollinger HW, Pirsch JD, Alessandro AM, Fernandez LA: Outcomes of simultaneous liver/kidney transplants are equivalent to kidney transplant alone: a preliminary report. Transplantation 2010, 90(1):52-60.
• [40]Karpinski M, Rush D, Jeffery J, Exner M, Regele H, Dancea S, Pochinco D, Birk P, Nickerson P: Flow cytometric crossmatching in primary renal transplant recipients with a negative anti-human globulin enhanced cytotoxicity crossmatch. J Am Soc Nephrol 2001, 12(12):2807-2814.
• [41]Mai ML, Ahsan N, Wadei HM, Genco PV, Geiger XJ, Willingham DL, Taner CB, Hewitt WR, Grewal HP, Nguyen JHH, et al.: Excellent renal allograft survival in donor-specific antibody positive transplant patients - role of intravenous immunoglobulin and rabbit antithymocyte globulin. Transplantation 2009, 87(2):227-232.
• [42]Riethmuller S, Ferrari-Lacraz S, Muller MK, Raptis DA, Hadaya K, Rusi B, Laube G, Schneiter G, Fehr T, Villard J: Donor-specific antibody levels and three generations of crossmatches to predict antibody-mediated rejection in kidney transplantation. Transplantation 2010, 90(2):160-167.
• [43]Scornik JC, Clapp W, Patton PR, Van Der Werf WJ, Hemming AW, Reed AI, Howard RJ: Outcome of kidney transplants in patients known to be flow cytometry crossmatch positive. Transplantation 2001, 71(8):1098-1102.
• [44]Vlad G, Ho EK, Vasilescu ER, Colovai AI, Stokes MB, Markowitz GS, Agati VD, Cohen DJ, Ratner LE, Suciu-Foca N: Relevance of different antibody detection methods for the prediction of antibody-mediated rejection and deceased-donor kidney allograft survival. Hum Immunol 2009, 70(8):589-594.
• [45]Zhang Q, Liang LW, Gjertson DW, Lassman C, Wilkinson AH, Kendrick E, Pham PTT, Danovitch GM, Gritsch HA, Reed EF: Development of posttransplant antidonor HLA antibodies is associated with acute humoral rejection and early graft dysfunction. Transplantation 2005, 79(5):591-598.
• [46]Bielmann D, Honger G, Lutz D, Mihatsch MJ, Steiger J, Schaub S: Pretransplant risk assessment in renal allograft recipients using virtual crossmatching. Am J Transplant 2007, 7(3):626-632.
• [47]Eng HS, Bennett G, Tsiopelas E, Lake M, Humphreys I, Chang SH, Coates PTH, Russ GR: Anti-HLA donor-specific antibodies detected in positive B-cell crossmatches by Luminex predict late graft loss. Am J Transplant 2008, 8(11):2335-2342.
• [48]Mahmoud KM, Ismail AM, Sheashaa HA, Gheith OA, Kamal MM, Ghoneim MA: Value of donor-specific antibody detection in first-graft renal transplant recipients with a negative complement-dependent cytotoxic crossmatch. Exp Clin Transplant 2009, 7(2):124-128.
• [49]Vaidya S, Partlow D, Barnes T, Gugliuzza K: Pretransplant soluble CD30 is a better predictor of posttransplant development of donor-specific antibodies and acute vascular rejection than panel reactive antibodies. Transplantation 2006, 82(12):1606-1609.
• [50]Gupta A, Iveson V, Varagunam M, Bodger S, Sinnott P, Thuraisingham RC: Pretransplant donor-specific antibodies in cytotoxic negative crossmatch kidney transplants: are they relevant? Transplantation 2008, 85(8):1200-1204.
• [51]Le Bas-Bernardet S, Hourmant M, Valentin N, Paitier C, Giral-Classe M, Curry S, Follea G, Soulillou JP, Bignon JD: Identification of the antibodies involved in B-cell crossmatch positivity in renal transplantation. Transplantation 2003, 75(4):477-482.
• [52]Phelan D, Mohanakumar T, Ramachandran S, Jendrisak MD: Living donor renal transplantation in the presence of donor-specific human leukocyte antigen antibody detected by solid-phase assay. Hum Immunol 2009, 70(8):584-588.
• [53]Poggio ED, Augustine JJ, Clemente M, Danzig JM, Volokh N, Zand MS, Hricik DE, Heeger PS: Pretransplant cellular alloimmunity as assessed by a panel of reactive T cells assay correlates with acute renal graft rejection. Transplantation 2007, 83(7):847-852.
• [54]Pratico-Barbato L, Conca R, Magistroni P, Leonardi G, Oda A, Rosati F, Leone E, Tacconella M, Roggero S, Segoloni GP, et al.: B cell positive cross-match not due to anti-HLA class I antibodies and first kidney graft outcome. Transpl Immunol 2008, 19(3–4):238-243.
• [55]Wang D, Wu WZ, Yang SL, Chen JH, Tan JM: Preoperative single-bolus high-dose antithymocyte globulin as induction therapy in sensitized renal transplant recipients. Chin Med J (Engl) 2006, 119(20):1683-1688.
• [56]Kimball P, Wagner B, King A, Fisher RA, Dawson S, Cotterell A, Posner M: Comparison of two drug regimens upon clinical outcome among renal transplant recipients with positive flow cytometric crossmatches. Clin Transplant 2002, 16(4):290-294.
• [57]Lefaucheur C, Loupy A, Hill GS, Andrade J, Nochy D, Antoine C, Gautreau C, Charron D, Glotz D, Suberbielle-Boissel C: Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation. J Am Soc Nephrol 2010, 21(8):1398-1407.
• [58]Meng HL, Jin XB, Li XT, Wang HW, Lu JJ: Impact of human leukocyte antigen matching and recipients’ panel reactive antibodies on two-year outcome in presensitized renal allograft recipients. Chin Med J (Engl) 2009, 122(4):420-426.
• [59]Noreen HJ, McKinley DM, Gillingham KJ, Matas AJ, Segall M: Positive remote crossmatch: impact on short-term and long-term outcome in cadaver renal transplantation. Transplantation 2003, 75(4):501-505.
• [60]Opelz G: Non-HLA transplantation immunity revealed by lymphocytotoxic antibodies. Lancet 2005, 365(9470):1570-1576.
• [61]Rebibou JM, Carvalho Bittencourt M, Saint-Hillier Y, Chabod J, Dupont I, Bittard H, Chalopin JM, Herve P, Tiberghien P: T-cell flow-cytometry crossmatch and long-term renal graft survival. Clin Transplant 2004, 18(5):558-563.
• [62]Bryan CF, Wakefield M, Reese JC, Shield CF, Warady BA, Winklhofer FT, Murillo D: Renal graft survival is not influenced by a positive flow B-cell crossmatch. Clin Transplant 2007, 21(1):72-79.
• [63]Mahoney RJ, Taranto S, Edwards E: B-cell crossmatching and kidney allograft outcome in 9031 United States transplant recipients. Hum Immunol 2002, 63(4):324-335.
• [64]Petero VG, Kaposztas Z, Kahan BD: Repeat renal allografts treated with sirolimus, cyclosporine, anti-thymocyte globulin induction and continuous steroids achieve similar immunosuppressive efficacy as primary transplants. Clin Transplant 2010, 24(2):243-251.
• [65]Thompson JS, Thacker Ii LR, Krishnan G: Human leukocyte antigens DR and AB and kidney retransplantation. Transplantation 2003, 75(5):718-723.
• [66]Aubert V, Venetz JP, Pantaleo G, Pascual M: Low levels of human leukocyte antigen donor-specific antibodies detected by solid phase assay before transplantation are frequently clinically irrelevant. Hum Immunol 2009, 70(8):580-583.
• [67]Gibney EM, Cagle LR, Freed B, Warnell SE, Chan L, Wiseman AC: Detection of donor-specific antibodies using HLA-coated microspheres: another tool for kidney transplant risk stratification. Nephrol Dial Transplant 2006, 21(9):2625-2629.
• [68]Roberti I, Vyas S, Pancoska C: Donor-specific antibodies by flow single antigen beads in pediatric living donor kidney transplants: single center experience. Pediatr Transplant 2007, 11(8):901-905.
• [69]Van Den Berg-Loonen EM, Billen EVA, Voorter CEM, Van Heurn LWE, Claas FHJ, Van Hooff JP, Christiaans MHL: Clinical relevance of pretransplant donor-directed antibodies detected by single antigen beads in highly sensitized renal transplant patients. Transplantation 2008, 85(8):1086-1090.
• [70]Verghese PS, Smith JM, McDonald RA, Schwartz SM, Nelson KA, Warner PR: Impaired graft survival in pediatric renal transplant recipients with donor-specific antibodies detected by solid-phase assays. Pediatr Transplant 2010, 14(6):730-734.
• [71]Willicombe M, Brookes P, Santos-Nunez E, Galliford J, Ballow A, McLean A, Roufosse C, Cook HT, Dorling A, Warrens AN, et al.: Outcome of patients with preformed donor-specific antibodies following alemtuzumab induction and tacrolimus monotherapy. Am J Transplant 2011, 11(3):470-477.
• [72]Poli F, Cardillo M, Scalamogna M: Clinical relevance of human leukocyte antigen antibodies in kidney transplantation from deceased donors: the North Italy Transplant program approach. Hum Immunol 2009, 70(8):631-635.
• [73]OPTN, SRTR: OPTN and SRTR Annual data report 2010. Available at http://optn.transport.hrsa.gov/data/annualreport.asp webcite. Access date: Jan 2012
• [74]OPTN, HRSA: OPTN and HRSA registry data 2012. Available at http://optn.transplant.hrsa.gov/latestData/step2.asp webcite. Access date: Jan 2012
• [75]Bray RA, Nolen JDL, Larsen C, Pearson T, Newell KA, Kokko K, Guasch A, Tso P, Mendel JB, Gebel HM: Transplanting the highly sensitized patient: the emory algorithm. Am J Transplant 2006, 6(10):2307-2315.
• [76]USRDS: US Renal Data System, USRDS 2011 Annual data report: atlas of chronic kidney disease and end-stage renal disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; Available at http://www.usrds.org/atlas11.aspx webcite. Access date: Feb 2012
• [77]Patel R, Terasaki PI: Significance of the positive crossmatch test in kidney transplantation. N Engl J Med 1969, 280(14):735-739.
• [78]Scornik JC, Meier-Kriesche HU: Blood transfusions in organ transplant patients: mechanisms of sensitization and implications for prevention. Am J Transplant 2011, 11(9):1785-1791.
• [79]Opelz G, Terasaki PI: Dominant effect of transfusions on kidney graft survival. Transplantation 1980, 29(2):153-158.
• [80]Marti HP, Henschkowski J, Laux G, Vogt B, Seiler C, Opelz G, Frey FJ: Effect of donor-specific transfusions on the outcome of renal allografts in the cyclosporine era. Transpl Int 2006, 19(1):19-26.
• [81]Lefaucheur C, Loupy A, Vernerey D, Duong-Van-Huyen JP, Suberbielle C, Anglicheau D, Verine J, Beuscart T, Nochy D, Bruneval P, et al.: Antibody-mediated vascular rejection of kidney allografts: a population-based study. Lancet 2013, 381(9863):313-319.
• [82]Macdougall IC, Obrador GT: How important is transfusion avoidance in 2013? Nephrol Dial Transplant 2013, 28(5):1092-1099.
• [83]Obrador GT, Macdougall IC: Effect of red cell transfusions on future kidney transplantation. Clin J Am Soc Nephrol 2013, 8(5):852-860.